<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>19(12)</volume><submitter>Tian Y</submitter><pubmed_abstract>Ataxin-2 is a protein containing a polyQ extension and intermediate length of polyQ extensions increases the risk of Amyotrophic Lateral Sclerosis (ALS). Down-regulation of Ataxin-2 has been shown to mitigate TDP-43 proteinopathy in ALS models. To identify alternative therapeutic targets that can mitigate TDP-43 toxicity, we examined the interaction between Ataxin-2 and TDP-43. Co-immunoprecipitation demonstrated that Ataxin-2 and TDP-43 interact, that their interaction is mediated through the RNA recognition motif (RRM) of TDP-43, and knocking down Ataxin-2 or mutating the RRM domains rescued TDP-43 toxicity in an iPSC-derived neuronal model with TDP-43 overexpression. To decipher the Ataxin-2 and TDP-43 interactome, we used co-immunoprecipitation followed by mass spectrometry to identify</pubmed_abstract><journal>PloS one</journal><pagination>e0308428</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11687654</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Deciphering the interactome of Ataxin-2 and TDP-43 in iPSC-derived neurons for potential ALS targets.</pubmed_title><pmcid>PMC11687654</pmcid><pubmed_authors>Heinsinger N</pubmed_authors><pubmed_authors>Lim UM</pubmed_authors><pubmed_authors>Hu Y</pubmed_authors><pubmed_authors>Klein B</pubmed_authors><pubmed_authors>Parmentier-Batteur S</pubmed_authors><pubmed_authors>Tian Y</pubmed_authors><pubmed_authors>Fernandis AZ</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Uslaner JM</pubmed_authors><pubmed_authors>Smith SM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Deciphering the interactome of Ataxin-2 and TDP-43 in iPSC-derived neurons for potential ALS targets.</name><description>Ataxin-2 is a protein containing a polyQ extension and intermediate length of polyQ extensions increases the risk of Amyotrophic Lateral Sclerosis (ALS). Down-regulation of Ataxin-2 has been shown to mitigate TDP-43 proteinopathy in ALS models. To identify alternative therapeutic targets that can mitigate TDP-43 toxicity, we examined the interaction between Ataxin-2 and TDP-43. Co-immunoprecipitation demonstrated that Ataxin-2 and TDP-43 interact, that their interaction is mediated through the RNA recognition motif (RRM) of TDP-43, and knocking down Ataxin-2 or mutating the RRM domains rescued TDP-43 toxicity in an iPSC-derived neuronal model with TDP-43 overexpression. To decipher the Ataxin-2 and TDP-43 interactome, we used co-immunoprecipitation followed by mass spectrometry to identify</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-01T21:55:58.12Z</modification><creation>2025-04-04T13:41:21.001Z</creation></dates><accession>S-EPMC11687654</accession><cross_references><pubmed>39739690</pubmed><doi>10.1371/journal.pone.0308428</doi></cross_references></HashMap>